February 1, 2007 --
The Centers for Medicare & Medicaid Services (CMS) announced today that it is
proposing to expand its coverage policy for carotid artery stenting (CAS).
A proposed National Coverage Determination (NCD) posted today includes a coverage expansion that reflects the latest evidence on the effective use of stenting, a procedure that reduces the occurrence of stroke in the Medicare population. Stroke is the third leading cause of death in the United States and the leading cause of serious, long-term disability. Approximately 70 percent of all strokes occur in people age 65 and older.
“CMS is committed to providing broader access to appropriate and innovative care to our beneficiaries in the management of their carotid artery disease,” said CMS Acting Administrator Leslie V. Norwalk, Esq. “We are working with health professionals and others to reduce the occurrence of stroke in the Medicare population.”
Under Medicare’s current policy, patients with no symptoms of carotid artery stenosis (narrowing of the arteries) and who are at high risk for CEA are only covered when CAS procedures are performed in FDA Category B Investigational Device Exemption (IDE) trials, FDA-approved post approval studies, or in accordance with the Medicare clinical trial policy. Medicare is proposing to expand coverage for CAS to this group of patients who have greater than 80 percent carotid artery stenosis.
Medicare is also proposing to modify coverage for patients who are 80 years of age and older. After a thorough review of the available evidence, significant concerns regarding the safety of CAS when performed in this older patient population have emerged. This proposed decision allows for coverage of patients age 80 and above only when CAS procedures are performed in Category B Investigational Device Exemption (IDE) trials, FDA-approved post approval studies, or in accordance with the clinical trial policy.
These proposed modifications in coverage enable Medicare to better serve its beneficiaries by providing access to this important service while ensuring safety. Additionally, this proposal formalizes the certification and recertification process for hospitals that are inserting carotid stents.
This NCD has resulted from extensive collaborations between CMS and various CAS stakeholders including medical professional organizations, other government agencies and hospitals. These collaborations have been essential in meeting the Agency’s goal of transparency and have been critical in ensuring that this important procedure is both safe and accessible for appropriate Medicare beneficiaries.
“The evidence on carotid artery stenting demonstrates its effectiveness in improving health outcomes for certain patients.” said CMS Chief Medical Officer Barry Straube, MD. “By requiring hospitals to certify their competency, CMS can help ensure patient safety and quality care for those undergoing this procedure.”
The proposed decision memorandum published today by CMS is on its web site, www.cms.hhs.gov. The posting of this proposed decision memorandum marks the beginning of a 30-day public comment period. Those wanting to submit comments should visit the tracking sheet for this analysis at http://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=194.
Source: Centers for Medicare & Medicaid Services
(Disclaimer: external
links to news, press releases and other timely information
sources are provided as a service by Angioplasty.Org, which
is not responsible for the content found on any external
sites. Items marked with a ($$) indicate that the external
site normally restricts viewing to paid subscribers. Other
sites may require free registration.
send comments & suggestions
to "info at angioplasty dot org"
Read our Privacy statement.
Angioplasty.Org is an editorially independent informational health
site
which has received unrestricted educational grants from Medtronic plc,
TCROSS NEWS, Toshiba
America
Medical Systems, Volcano
Corporation, Terumo
Medical Corporation
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY
